Who is sponsoring NCT04294862?

NCT04294862 is sponsored by TenNor Therapeutics Limited.

What condition does NCT04294862 study?

NCT04294862 studies Prosthetic Joint Infection.

What is the status of NCT04294862?

NCT04294862 is currently COMPLETED.

Last reviewed 2022-10-19 · How we verify

Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty

NCT04294862 PHASE1 COMPLETED

This study will investigate TNP-2092 distribution into joint tissues in participants undergoing a total hip arthroplasty (THA) or a total knee arthroplasty (TKA). Tissue distribution is the primary objective, and plasma pharmacokinetics (PK), safety, and tolerability are secondary objectives.

Details

Lead sponsor	TenNor Therapeutics Limited
Phase	PHASE1
Status	COMPLETED
Enrolment	13
Start date	Mon Mar 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Prosthetic Joint Infection

Interventions

TNP-2092

Countries

United States